TLSI

Trisalus Life Sciences Stock Analysis

AI Rating

Fair
  • Quality6/10
  • Growth↓ 3/10
  • Momentum↓ 4/10
Trisalus Life Sciences sales and earnings growth
TLSI Growth
Neutral
  • Revenue Y/Y↑ 49.52%
  • EPS Y/Y↓ -2.02%
  • FCF Y/Y↑ 50.91%
Trisalus Life Sciences gross and profit margin trends
TLSI Profitability
Good
  • Gross margin ↑ 84.00%
  • EPS margin↓ -174.20%
  • ROIC↓ -97.00%
Trisalus Life Sciences net debt vs free cash flow
TLSI Risk
Great
  • Debt / Equity↓ -1.3
  • Debt / FCF↓ 0.5
  • Interest coverage↓ -6.7

Trisalus Life Sciences stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Medical Devices stocks ↗